Compare XPOF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | BNR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | China |
| Employees | 340 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.4M | 252.7M |
| IPO Year | 2021 | 2019 |
| Metric | XPOF | BNR |
|---|---|---|
| Price | $5.66 | $16.16 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.13 | N/A |
| AVG Volume (30 Days) | ★ 336.1K | 18.8K |
| Earning Date | 05-07-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,092,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | $6.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.83 | $2.49 |
| 52 Week High | $11.14 | $41.72 |
| Indicator | XPOF | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 31.24 | 41.59 |
| Support Level | $5.37 | $15.57 |
| Resistance Level | $6.18 | $23.19 |
| Average True Range (ATR) | 0.31 | 1.27 |
| MACD | -0.10 | -0.14 |
| Stochastic Oscillator | 8.58 | 24.83 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.